Clinical Trial Update: Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating Lenvatinib with Pembrolizumab, with or without branched-chain amino acids, for unresectable hepatocellular carcinoma; the trial is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Fudan University | Conditions: HCC - Hepatocellular Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING